Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Warfarin Duration for HIT
NCT03147638Phase 3Unknown
- Sponsor
- Marshall University
- Start
- Jan 2017
- Primary completion
- Jan 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of warfarin in heparin-induced thrombocytopenia (HIT) (2 arms), sponsored by Marshall University. Primary endpoints: All cause hospitalization at 6 months, side effects of Warfarin treatment at 6 months and 1 more. Status: unknown.
02
Drugs
warfarin
03
Conditions
heparin-induced thrombocytopenia (HIT)
Beyond the preview
Go deeper on NCT03147638.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03147638.